Back to discover
Disease

Paraproteinemias

Late-stage therapeutic developmentEmerging research
MeSHParaproteinemias
1
Publications
6
Clinical trials
10
Associated genes
1
Related proteins
2019
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
4
Active
1
Late-stage
1
Completed
Recruiting

Daratumumab in Monoclonal Gammopathy of Renal Significance in Finland

Phase 2 · Recruiting · Helsinki University Central Hospital

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administrated in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Phase 1/2 · Recruiting · Hellenic Society of Hematology

A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 · Recruiting · Kelonia Therapeutics, Inc.

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.

Phase 1 · Recruiting · OriCell Therapeutics Co., Ltd.
Recently completed

The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Phase 2 · Completed · National Institute of Neurological Disorders and Stroke (NINDS)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Leading journals1
  • Nature reviews. Nephrology1
Leading researchers8
  • Batuman V1
  • Bridoux F1
  • Chaidos A1
  • Cockwell P1
  • D'Agati VD1
  • Dispenzieri A1
  • Fermand JP1
  • Fervenza FC1
Affiliations (unnormalised)6
  • Abramson Cancer Center1
  • Amyloidosis Research and Treatment Center1
  • Arkana Laboratories1
  • Centre de Référence des Amyloses Primitives et des Autres Maladies par Dépôts d'Immunoglobuline1
  • Centre for Haematology1
  • Centre Hospitalier Universitaire et Université de Poitiers1

Associated genes

10 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

TNFRSF13B0.47TNFRSF170.37ULK40.36ELL20.32NFIC0.29SLC23A20.28MNAT10.22SOHLH20.21PRR140.05KCNJ40.05

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Tumor necrosis factor receptor superfamily member 17via TNFRSF170.37

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.

Identifiers
MeSHParaproteinemias
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.